The Executive Committee designs and implements Group strategy, ensuring that targets are met for the benefit of our clients, shareholders, and partners.
Dr. André Choulika, Chief Executive Officer
André Choulika, Ph.D., is one of the founders of Cellectis and has been Chairman of the Board and Chief Executive Officer since 2000. He has also been President of Calyxt since August 2010. From 1997 to 1999, Dr. Choulika worked as a post-doctoral fellow in the Division of Molecular Medicine at Boston Children’s Hospital, where he was a pioneer in the analysis and use of meganucleases to modify complex genomes. After receiving his Ph.D. in molecular virology from the University of Paris VI (Pierre et Marie Curie), he completed a research fellowship in the Harvard Medical School Department of Genetics. André Choulika also has management training from the HEC (Challenge +).
Dr. Julia Berretta, VP Business Development and Strategic Planning
Julia Berretta, Ph.D., joined Cellectis in 2010 in the scientific alliance and business development department. She has served as VP Business Development and Strategic Planning since 2014. Prior to joining Cellectis, she worked as a researcher at the CNRS in Gif-sur-Yvette. Julia Berretta received her Ph.D. in molecular biology from the Université Paris XI, and holds a specialized Master’s Degree in innovation management from Neoma Business School.
Dr. Philippe Duchateau, Chief Scientific Officer
Philippe Duchateau, Ph.D., joined Cellectis in 2001 to pioneer the field of gene editing and he has served as Chief Scientific Officer since 2012. After receiving his Ph.D. in 1993 in biochemistry and molecular biology at the Institut Pasteur (Lille, France), he completed a research fellowship from 1993 to 2001 at the University of California, San Francisco, within the Cardiovascular Research Institute. As head of Cellectis’ Research department since 2004, he helped to the development of Cellectis’ technologies.
Eric Dutang, Chief Financial Officer
Eric Dutang, Certified Public Accountant in France, joined Cellectis as Deputy Chief Financial Officer in May 2015. Eric began his career as financial auditor with KPMG, first in Paris for five years and then in New York for two years. He worked for listed companies in France and the U.S. such as Vivendi, Veolia Environnement or Cablevision. He then became a member of the transactions and advisory teams in Paris for seven years where he carried out acquisitions/disposals for listed companies and private equity funds. After serving at KPMG, he worked on international business developments for French public listed groups, including Air Liquide and Thales. Eric holds a Master of Finance and Executive MBA from HEC Paris (France)/Babson Massachusetts (USA).
Dr. Mathieu Simon, Executive Vice President, Chief Operating Officer
Mathieu Simon, MD, has served as Executive Vice-President Chief Executive Officer of Cellectis Therapeutics since 2012 and as Chief Operating Officer since 2013. Dr Mathieu Simon is also Member of Cellectis Board of Directors since 2013. Prior to joining Cellectis, Dr. Simon was Senior Vice President Head of Global Pharmaceutical Operations at Pierre Fabre S.A. From 1994 to 2010, Dr Simon has served at Wyeth Pharmaceuticals in both senior corporate and regional roles (Head of International Marketing and Medical Affairs and managing Director of several Wyeth Affiliates). Dr Simon today is an advisor at the European Commission D.G. Research and Innovation with a special expertise in Market Access and pricing initiation. In addition to his Cellectis role, Dr Simon is also Senior Strategic Advisor at Messier Maris Partners, an international investment-banking boutique located in New York and Paris.
Dr. David Sourdive, Executive Vice President Technical Operations
David Sourdive, Ph.D., is a co-founder of Cellectis and has held the position of Executive Vice President, Corporate Development from 2008 to 2016. His current position is Executive Vice President, Technical Operations. Dr. Sourdive has also been a member of Cellectis’ Board of Directors since 2000. Since 2014, Dr. Sourdive has also served on the board of directors of Mediterranean Institute for Life Sciences. David Sourdive graduated from the École Polytechnique and received his Ph.D. in molecular virology at the Institut Pasteur. He also has management training from the HEC (Challenge +).
Marie-Bleuenn Terrier, General Counsel
Marie-Bleuenn Terrier joined Cellectis as Legal Counsel in 2008, and was appointed General Counsel in 2013. Prior to joining Cellectis, she worked as Legal Counsel for Pfizer from 2004 to 2006, and for Boehringer Ingelheim from 2006 to 2008. Marie-Bleuenn Terrier also serves as Secretary of the Board of Directors since 2015. She holds a Master’s degree in Law from the Panthéon La Sorbonne University in Paris.